Drug · DIN 02511061
ABRILADA
SINGLE-DOSE PREFILLED SYRINGE
Yes: authorized and sold in Canada
Authorized, and the company reports that it sells it in Canada.
Status Marketed since March 13, 2023; first marketed March 13, 2023.
- Drug Identification Number (DIN)
- 02511061
- Company (DIN owner)
- Pfizer Canada UlcKirkland, Quebec, Canada
- Schedule
- Schedule D; Prescription
- Dosage form
- Solution
- Route
- Subcutaneous
- Therapeutic class (ATC)
- Adalimumab L04AB04
- Class
- Human
- Record last updated
- August 10, 2026
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| ADALIMUMAB | 20 MG | 0.4 ML |
Notices of Compliance
Health Canada approvals that name this DIN.
- January 14, 2021: NOC 25020New Drug Submission (NDS)
Other DINs named ABRILADA
- DIN 02511045 · Marketed
- DIN 02511053 · Marketed
- DIN 02511088 · Approved
- DIN 02511096 · Approved